Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Microsemi/Cyberonics

This article was originally published in The Gray Sheet

Executive Summary

Next generation Cyberonics NeuroCybernetic Prosthesis (NCP) vagus nerve stimulator for treatment of epilepsy will feature Microsemi's custom integrated circuits, following a long-term licensing deal announced by the firms May 30. Microsemi's "system-on-chip" will allow the new version to be programmable. The beefed-up device will be tested in depression, anxiety, Alzheimer's, obesity, cardiac arrhythmia, and pain, firm says

You may also be interested in...



Biopharma Quarterly Dealmaking Statistics, Q4 2019

Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.

Europe Restricts Cyproterone Use Due To Meningioma Risk; Companies To Conduct Studies

The risk of developing meningioma with cyproterone-containing medicines is rare, but it is serious enough to merit restrictions on how such products are used, according to the European Medicines Agency.

Execs On The Move, February 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

UsernamePublicRestriction

Register

MT014966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel